277 related articles for article (PubMed ID: 32540465)
21. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
22. YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study.
Senetta R; Duregon E; Sonetto C; Spadi R; Mistrangelo M; Racca P; Chiusa L; Munoz FH; Ricardi U; Arezzo A; Cassenti A; Castellano I; Papotti M; Morino M; Risio M; Cassoni P
PLoS One; 2015; 10(4):e0123759. PubMed ID: 25875173
[TBL] [Abstract][Full Text] [Related]
23. Immune biological rationales for the design of combined radio- and immunotherapies.
Hader M; Frey B; Fietkau R; Hecht M; Gaipl US
Cancer Immunol Immunother; 2020 Feb; 69(2):293-306. PubMed ID: 31953578
[TBL] [Abstract][Full Text] [Related]
24. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
[TBL] [Abstract][Full Text] [Related]
25. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
26. Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer.
Ogura A; Akiyoshi T; Yamamoto N; Kawachi H; Ishikawa Y; Mori S; Oba K; Nagino M; Fukunaga Y; Ueno M
Eur J Cancer; 2018 Mar; 91():11-20. PubMed ID: 29328976
[TBL] [Abstract][Full Text] [Related]
27. Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?
Martin-Romano P; Adam J; Scoazec JY; Gouy S; Levy A; Baldini C; Champiat S; Soria JC; Massard C; Marabelle A; Deutsch E; Hollebecque A
Front Immunol; 2021; 12():745146. PubMed ID: 34804027
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
[TBL] [Abstract][Full Text] [Related]
29. The role of exosomal PD-L1 in tumor progression and immunotherapy.
Xie F; Xu M; Lu J; Mao L; Wang S
Mol Cancer; 2019 Oct; 18(1):146. PubMed ID: 31647023
[TBL] [Abstract][Full Text] [Related]
30. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
Wang H; Franco F; Ho PC
Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
[TBL] [Abstract][Full Text] [Related]
31. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies.
Patel SA; Minn AJ
Immunity; 2018 Mar; 48(3):417-433. PubMed ID: 29562193
[TBL] [Abstract][Full Text] [Related]
32. Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial.
Li X; Warren S; Pelekanou V; Wali V; Cesano A; Liu M; Danaher P; Elliott N; Nahleh ZA; Hayes DF; Hortobagyi GN; Barlow WE; Hatzis C; Pusztai L
J Immunother Cancer; 2019 Apr; 7(1):88. PubMed ID: 30967156
[TBL] [Abstract][Full Text] [Related]
33. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
34. Prostate cancer immunotherapy: where are we and where are we going?
De Velasco MA; Uemura H
Curr Opin Urol; 2018 Jan; 28(1):15-24. PubMed ID: 29095729
[TBL] [Abstract][Full Text] [Related]
35. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
[TBL] [Abstract][Full Text] [Related]
36. Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets.
Kumar AR; Devan AR; Nair B; Vinod BS; Nath LR
Mol Biol Rep; 2021 Dec; 48(12):8075-8095. PubMed ID: 34671902
[TBL] [Abstract][Full Text] [Related]
37. Current status and limitations of immunotherapy for breast cancer.
Tokumaru Y; Joyce D; Takabe K
Surgery; 2020 Mar; 167(3):628-630. PubMed ID: 31623855
[No Abstract] [Full Text] [Related]
38. Targeting Innate Immunity to Enhance the Efficacy of Radiation Therapy.
Dar TB; Henson RM; Shiao SL
Front Immunol; 2018; 9():3077. PubMed ID: 30692991
[TBL] [Abstract][Full Text] [Related]
39. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy.
Lei X; Lei Y; Li JK; Du WX; Li RG; Yang J; Li J; Li F; Tan HB
Cancer Lett; 2020 Feb; 470():126-133. PubMed ID: 31730903
[TBL] [Abstract][Full Text] [Related]
40. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
